Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study

BACKGROUND: Epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) therapy is the standard treatment for advanced non‐small cell lung cancer (NSCLC) harboring common EGFR mutations, such as exon 19 deletion or L858 point mutation. However, the effectiveness of EGFR‐TKIs for patients w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Kanazu, Masaki, Mori, Masahide, Kimura, Madoka, Nishino, Kazumi, Shiroyama, Takayuki, Nagatomo, Izumi, Ihara, Shoichi, Komuta, Kiyoshi, Suzuki, Hidekazu, Hirashima, Tomonori, Kumagai, Toru, Imamura, Fumio
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7779206/
https://ncbi.nlm.nih.gov/pubmed/33124128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13718
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados